Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

NCT05768035 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

BIOLOGICAL: Allogeneic T cell progenitors, cultured ex-vivo

Sponsor

Smart Immune SAS